Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance

MYRIAD GENETICS INC

2024-Q1 EPS reported -$0.29 revenue$202,200,000

Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.
Adjusted EPS -$0.01 vs -$0.21 YoY; positive adjusted EBITDA $4M vs -$19M.
Revenue growth driven by Prenatal (+22%), Pharmacogenomics (+21%), Hereditary Cancer (+16%).
Announced sale of EndoPredict to Eurobio Scientific; retains U.S. license.
Reiterates FY2024 guidance: revenue $820-840M, adjusted EBITDA $20-30M, adjusted EPS $0.00-$0.05.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $202.2 million
Net income: $26 million
EPS: $(0.29)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-24-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.